| The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer |
| Received:May 23, 2022 Revised:September 12, 2022 Click here to download the full text |
| Citation of this paper:MA Jing,HU Bo,YANG Zhang-fu,XU Yang.The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer[J].Chinese Journal of Clinical Medicine,2022,29(6):1022-1029 |
| Hits: 870 |
| Download times: 234 |
| Author Name | Affiliation | E-mail | | MA Jing | Department of Liver Surgery, Zhongshan Hospital, Fudan University, Liver Cancer Institute of Fudan University, Shanghai 200032, China | | | HU Bo | Department of Liver Surgery, Zhongshan Hospital, Fudan University, Liver Cancer Institute of Fudan University, Shanghai 200032, China | | | YANG Zhang-fu | Department of Liver Surgery, Zhongshan Hospital, Fudan University, Liver Cancer Institute of Fudan University, Shanghai 200032, China | | | XU Yang | Department of Liver Surgery, Zhongshan Hospital, Fudan University, Liver Cancer Institute of Fudan University, Shanghai 200032, China | drxuyang@qq.com |
|
| Abstract:Anti-programmed death receptor 1 (PD-1) and its ligand (PD-L1) antibodies have been applied in the clinical treatment of a variety of tumors, including advanced biliary tract cancer (BTC), and have achieved significant efficacy. Meanwhile, PD-1/PD-L1 antibodies also result in many adverse effects (AEs), such as rush, diarrhea, liver dysfunction and so on. This paper briefly reviews efficacy and AEs of anti-PD-1/PD-L1 antibodies monotherapy and combination therapy in BTC, and tries to formulate strategies of AEs management. |
| keywords:biliary tract neoplasms immune checkpoint inhibitors adverse events management |
| HTML View Full Text View/Add Comment Download reader |
|
|
|